An additional rituximab dose in patients with pemphigus and at least one predictor of relapse may reduce the relapse rate, according to the results of a multicenter French study.

Patients received an infusion of either rituximab or placebo on days 1, 8, 15 and 22 of the study; the four infusions constituted a single course of treatment. The primary outcome measure was the ...

Evidence that rituximab affects cytokine production by B cells includes reports of cytokine-release syndromes in patients with hematological disease, which potentially accounts for some infusion ...